Get startedLog in
    Picture of Damora Therapeutics logo

    DMRA — Damora Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Galecto Announces First Patient Treated In Phase 2A Trial Of The Oral Loxl2 Inhibitor Gb2064 In Myelofibrosis (The Mylox-1 Trial)

    Picture of Damora Therapeutics logoDamora Therapeutics
    18/08/2021 13:16
    Aug 18 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO ANNOUNCES FIRST PATIENT TREATED IN PHASE 2A TRIAL
OF THE
ORAL LOXL2 INHIBITOR GB2064 IN MYELOFIBROSIS (THE MYLOX-1 TRIAL)

Source text for Eikon:  ID:nGNX4JH7s8 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Damora Therapeutics

    See all news